ClinicalTrials.gg
CompletedNCT02803996Updated Dec 21, 2016

Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers

A Phase 1 interventional study of Aramchol and Placebo in Healthy Volunteers, sponsored by Galmed Pharmaceuticals Ltd. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-21.

Sponsored by Galmed Pharmaceuticals Ltd · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a single-site, randomized, double-blind, double dummy, placebo-controlled single and multiple doses study of Aramchol in healthy Chinese volunteers. The subject population that was enrolled for Aramchol 004 was not specifically designed to understand the PK profile of Aramchol in subjects of Chinese descent. Therefore, this study (Aramchol 015) has been undertaken to ascertain the PK profile of Aramchol following single and multiple doses in a Chinese population under fed conditions utilizing the light breakfast from Aramchol 004.

This study will consist of two parts and the subjects will be assigned to two parts.

In each part of the study, subjects will be enrolled in the study within 28 days of screening.

Read the detailed description

In each part of the study, subjects will be enrolled in the study within 28 days of screening. The study will consist of two parts, and the subjects will be assigned as follows: Part A- single escalating doses This part of the study is a single-site, randomized, double-blind, double dummy, placebo-controlled single-dose study of Aramchol in healthy Chinese volunteers. The purpose of Part A is to evaluate the PK, safety and tolerability of Aramchol tablets at single doses of either 400 mg or 600 mg.

Thirty-two (32) subjects will participate in this part of the study and will be randomized to receive a single-dose of 400 mg Aramchol, 600 mg Aramchol, or Placebo. Drug administration will be preceded by a light breakfast consumed within 1 hour prior to dosing. All drugs will be administered by the study staff. In order to maintain blinding, all subjects will receive two tablets on each dosing, according to the following administrations:

  • Cohort A: 1 x 200 mg Placebo tablet + 1 x 400 mg Aramchol tablet (12 subjects)
  • Cohort B: 1 x 200 mg Aramchol tablet + 1 x 400 mg Aramchol tablet (12 subjects)
  • Cohort C: 1 x 200mg Placebo tablet + 1 x 400 mg Placebo tablet (8 subjects) Subjects will be admitted in-house in the evening before the first study drug administration (Day 0) and will remain in-house for 36 hours after dosing. Blood samples for Aramchol concentrations will be drawn for 36 hours at designated time points as described below. Additional ambulatory samples will be collected at 48, 72, 96, and 144 hours postdose. Subjects will be continuously monitored for safety. An End-of Study/Safety Follow-up visit will take place on the last PK sampling day, ie, 144 hours after the last dose administration.

If the PK profile from Part A is similar to the existing PK data in non- Chinese subjects, then the study may be stopped. If the PK profile is different, then Part B of the study may be performed.

Part B- multiple escalating doses Part B of the study is a single-site, randomized, double-blind, doubledummy, placebo-controlled multiple-dose study of Aramchol in healthy Chinese volunteers. The purpose of this part is to evaluate the PK, safety and tolerability of Aramchol tablets at multiple administrations of two different doses. Thirty-two (32) subjects will participate in this part of the study and will be equally randomized to receive 400 mg Aramchol, 600 mg Aramchol, or Placebo for 10 consecutive days. Screening for Part B may begin during PK analysis of Part A. Part A subjects can enroll into Part B with sponsor approval. Drug administration will be preceded by a light breakfast consumed within 1 hour prior to dosing. All drugs will be administered by the study staff. In order to maintain blinding, all subjects will receive two tablets on each dosing, according to the following administrations:

  • Cohort D: 1 x 200 mg Placebo tablet + 1 x 400 mg Aramchol tablet (12 subjects)
  • Cohort E: 1 x 200 mg Aramchol tablet + 1 x 400 mg Aramchol tablet (12 subjects)
  • Cohort F: 1 x 200 mg Placebo tablet + 1 x 400 mg Placebo tablet (8 subjects) Subjects will be admitted in-house in the evening before the first study drug administration (Day 0) and will remain in-house for 24 and 36 hours after first (Day 1) and last (Day 10) doses, respectively; subjects will return for all other visits. PK blood samples will be drawn on Day 1 over 24 hours at designated time points as described below. Additionally, pre-dose (trough) samples will be drawn before dosing on Days 2, 3, 4, 5, 7, 8, and 9. On Day 10, blood samples will be collected over 36 hours at designated time points as described below and during additional visits at 48, 96, 120, 144, 168 and 192 hours post-dose. Subjects will be continuously monitored for safety. An End-of Study/Safety Follow-up visit will take place on the last PK sampling day, ie, 192 hours after the last dose administration.
02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Galmed Pharmaceuticals Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects, born in China, both parents of Chinese descent, aged at screening between 18-50 years old (inclusive), and having not lived outside of China for more than 10 years (in total, confirmed by verbal report).
  2. ≥ 18.0 and ≤ 30.0.
  3. Subjects in general good health in the opinion of the investigator as determined by medical history, vital signs and physical examination.
  4. No significant abnormalities in (eg, prolonged , prolonged PR interval) done at screening and on Days (0) before dosing session.
  5. No abnormalities in hematology, blood chemistry, or urinalysis lab tests at screening.
  6. No known history of alcohol or drug abuse. Subjects with negative urinary drugs of abuse (DOA) screen determined on Day (0) before dosing session(s).
  7. Negative (HIV), , and serology tests as evaluated at screening.
  8. Negative urine pregnancy tests at screening and at check-in (women of only).
  9. . Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.
  10. All subjects must agree to use a highly effective method of during the study and up to 15 days after the last study drug administration. A highly effective method of birth control is considered to be one of the following:

    • An oral or implanted hormonal method of contraception (if it had been used for ≥3 months prior to study drug administration) while also using a barrier method (ie, condom or diaphragm)
    • A hormone or copper intrauterine device if it had been in place for ≥3 months prior to study drug administration (subjects using nonhormonal or copper intrauterine devices were also required to use a barrier method of contraception)
    • A vasectomized partner
    • Total abstinence is acceptable; however, the subject is required to use a highly effective method of contraception if the subject decides subsequently not to abstain
    • Periodic abstinence around ovulation is not considered acceptable
    • Women who are either surgically sterilized or (last menstrual period at least 1 year prior to the screening visit) are exempt from this requirement. If medical records are not available to document sterility, urine pregnancy testing will be performed at screening and check-in.
  11. Subjects must provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Documented history or on-going symptoms of any gastrointestinal disorder involving motility, gastric acid or gastric emptying or malabsorption, including but not limited to, peptic ulcer disease, gastroesophageal reflux, dyspepsia, gastroparesis, chronic diarrhea, chronic constipation, gall bladder disease, pancreatitis, lactose intolerance and celiac disease.
  2. History of esophageal, gastric, biliary, or intestinal surgery (excluding herniotomy and appendectomy which are not related to gastrointestinal disorders).
  3. Known history of significant medical disorder, which in the investigator's judgment contraindicates administration of the study medications.
  4. Any abnormality upon physical examination or in the clinical laboratory tests at screening visit.
  5. Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal or dietary supplements within 14 days prior to dosing. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until 24 hours prior to the study drug administration.
  6. Subjects who have taken anticholinergic or other drugs known to affect gastrointestinal motility within 7 days prior to the first dosing.
  7. Treatment with any drugs with known hepatic enzyme-inducing or inhibiting agents (eg, barbiturates, phenothiazines, cimetidine, carbamazepine) within 30 days prior to dosing.
  8. Known clinically significant and/or allergy to any drugs.
  9. Subjects with recent significant change in body weight (±10% within 3 months of screening).
  10. Any acute illness (eg, acute infection) within 48 hours prior to the first study drug administration, which is considered of significance by the Principal Investigator.
  11. Participation in another clinical trial with drugs, received within 3 months prior to dosing (calculated from the previous study's last dosing date).
  12. Female subjects who are pregnant or breastfeeding.
  13. Subjects who donated blood in the three months or received blood or plasma derivatives in the six months preceding study drug administration.
  14. Inability to fast or consume the food provided in the study (including any clinically significant known food allergies or food restrictions).
  15. Subjects who are non-cooperative, unwilling or unable to communicate with the investigators and site staff (ie, language problem, poor mental development or impaired cerebral function).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Part A- Single Dose- 400 mg Aramchol

    Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.

    Drug: Aramchol

  • Active comparator
    Part A- Single Dose- 600 mg Aramchol

    Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.

    Drug: Aramchol

  • Placebo comparator
    Part A-Single Dose-Placebo

    Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.

    Drug: Placebo

  • Active comparator
    Part B-Multiple Dose-400 mg Aramchol

    Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.

    Drug: Aramchol

  • Active comparator
    Part B-Multiple Dose-600 mg Aramchol

    Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.

    Drug: Aramchol

  • Placebo comparator
    Part B-Multiple Dose-Placebo

    Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.

    Drug: Placebo

Interventions

  • Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.

  • DrugPlacebo

    Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose.Part C: Dosing days 1-10

  2. Area under the plasma concentration time curve (AUC)

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose.Part C: Dosing days 1-10.

  3. Maximum plasma concentration (Cmax)

    Time frame: Part B: Day 1 and day 10

  4. Area under the plasma concentration time curve (AUC)

    Time frame: Part C: Day 1 and Day 10

Secondary outcomes

  1. Adverse Event (AE) Profile

    Adverse Events records in patients file

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose. Part B:Dosing days 1-10

  2. Adverse Event (AE) Profile

    Adverse Events records in patients file

    Time frame: Part B: Dosing days 1 and 2: pre-dose (within 60 min before first dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18 and 24 (before second dosing) hours after drug administration+ day 3-10

  3. Clinical Laboratory Safety Tests

    Blood Tests

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose. Part B:Dosing days 1-10

  4. Clinical Laboratory Safety Tests

    Blood Tests

    Time frame: Part B:Dosing days 1 and 2: pre-dose (within 60 min before first dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18 and 24 (before second dosing) hours after drug administration+ day 3-10

07

Study locations

1 site
  • WCCT Global, LLC.
    Cypress, California 90630, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Sep 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2016
First posted
Jun 17, 2016
Start
May 2016
Primary completionActual
Sep 2016
CompletionActual
Dec 2016
Last update
Dec 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02803996
Lead sponsor
Galmed Pharmaceuticals Ltd
Collaborators
WCCT Global, Alpha IRB, Analyst Research Laboratories, Kramer Consulting, LLC, Diamond Pharma Services Regulatory Affairs Consultancy
Responsible party
Sponsor
First posted
Jun 17, 2016
Start date
May 2016
Primary completion
Sep 2016
Completion
Dec 2016
Last update
Dec 21, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion